Systemic lupus erythematosus Trials in Brooklyn, United States
Conditions / Systemic lupus erythematosus / Brooklyn, United States
Clinical trials for Systemic lupus erythematosus investigate a range of treatment strategies and patient populations.
33 total trials for this combination
Showing top 10 of 33 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00035308 | Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease | COMPLETED | PHASE3 |
| NCT01205438 | A Study of LY2127399 in Participants With Systemic Lupus Erythematosus | COMPLETED | PHASE3 |
| NCT03252587 | An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus | COMPLETED | PHASE2 |
| NCT01484496 | A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE) | COMPLETED | PHASE3 |
| NCT00410384 | A Study of Belimumab in Subjects With Systemic Lupus Erythematosus | COMPLETED | PHASE3 |
| NCT04294667 | A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus | COMPLETED | PHASE3 |
| NCT06617325 | A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus | RECRUITING | — |
| NCT01408576 | Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus | COMPLETED | PHASE3 |
| NCT03616912 | A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus | TERMINATED | PHASE3 |
| NCT05843643 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING | — |